Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
32 hedge funds and large institutions have $14.7M invested in Acorda Therapeutics in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 7 closing their positions.
83% more call options, than puts
Call options by funds: $898K | Put options by funds: $491K
6% less funds holding
Funds holding: 34 → 32 (-2)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
18% less capital invested
Capital invested by funds: $18.1M → $14.7M (-$3.33M)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWM
AE Wealth Management
Topeka,
Kansas
|
+$168K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$162K |
| 3 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
+$98.7K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$79.8K |
| 5 |
AWM
Apollon Wealth Management
Mount Pleasant,
South Carolina
|
+$62.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.75M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$645K |
| 3 |
Squarepoint
New York
|
-$235K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$185K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$147K |
ACOR Hedge Fund Activity: Q3 2021 in Review
32 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q3 2021, worth a combined $14.7M — down 18% from $18.1M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ACOR and 5 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 8 added.
The largest buyer was AE Wealth Management, opening a new position worth an estimated $168K. The largest seller was Point72 Asset Management, cutting an estimated $1.75M.
- 32 institutional investors held Acorda Therapeutics (ACOR) as of Q3 2021, down from 34 in Q2 2021.
- Funds reported $14.7M of Acorda Therapeutics stock for Q3 2021, down 18% quarter-over-quarter.
- 5 funds opened new Acorda Therapeutics positions in Q3 2021 and 7 closed out, a net change of -2 holders.
- The largest Acorda Therapeutics buyer in Q3 2021 was AE Wealth Management, an estimated $168K added.
- The largest Acorda Therapeutics seller in Q3 2021 was Point72 Asset Management, an estimated $1.75M sold.
Based on aggregated 13F filings for Q3 2021.